Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A phase III, open-label, multi-centre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix™), given as a primary vaccination at 4.5 months and 6.5 months post-transplantation, in autologous stem cell/ bone marrow transplant recipients aged 18 years and older.
Varicella Vaccine
208133/178
NCT00792623
Varicella
Phase 2
 
An annotated case report form is not available for this study. A blank case report form will be provided.
September 2015

Powered by ideaPoint, Inc.